The AQUARIUS trial: Aliskiren does not slow progression of atherosclerosis

The renin-angiotensin-aldosterone system (RAAS) appears to have an important role in the development of atherosclerosis.  The Aliskiren Quantitative Atherosclerosis Regression Intravascular Ultrasound Study (AQUARIUS) sought to determine if direct renin inhibition with aliskiren slows atherosclerosis progression in patients with already controlled blood pressure. […]

Read More…